Overview
- The Financial Times reported Monday that AstraZeneca and Bristol Myers Squibb have held preliminary talks about a deal that would be worth roughly $400 billion if completed.
- Investors punished the news with AstraZeneca shares falling sharply, recording drops as large as about 7 to 9 percent in early trading after the report.
- Both companies have declined to make substantive public comments and sources caution the discussions are preliminary and could be delayed or collapse.
- Analysts say the merger would face major regulatory hurdles because the firms have overlapping oncology businesses, including competing immuno‑oncology drugs that are likely to attract U.S. antitrust review under the Trump administration.
- The reported talks fit into AstraZeneca's recent U.S. push, which includes a direct New York listing and large U.S. investment commitments, and the outcome could affect the company's ties to the U.K. and the London market.